Quick Takeaways
- Invus Global Management, LLC filed SCHEDULE 13G for Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value (RANI).
- Disclosed ownership: 10%.
- Date of event: 16 Oct 2025.
Invus Global Management, LLC - 16 Oct 2025 SCHEDULE 13G Report for Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value (RANI)
- Filing Manager
- Invus Global Management, LLC
- Reporting Manager
- Raymond Debbane
- Symbol
- RANI
- Shares outstanding
- 98,357,467 shares
- Disclosed Ownership
- 9,825,911 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 23 Oct 2025, 17:05:17 UTC
- Date of event
- 16 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Invus Global Management, LLC disclosed 10% ownership in Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value (RANI) on 16 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Oct 2025, 17:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (8)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 8.8% | 8,617,378 | 8,617,378 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 1.3% | 1,208,533 | 1,208,533 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 1.3% | 1,208,533 | 1,208,533 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 1.3% | 1,208,533 | 1,208,533 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 10% | 9,825,911 | 9,825,911 | 0 | /s/ Raymond Debbane | Raymond Debbane |